The UK's Antisoma is sounding bullish about its licensing prospects for its flagship drug, AS1404, a potential blockbuster cancer therapy. Antisoma chief Glyn Edwards says that he's in talks with a number of big pharma companies, but couldn't say exactly when a deal might be completed. Antisoma also announced positive Phase II data for AS1404 today. Report